Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISCT 2020 | Respiratory pathology of COVID-19 and potential for MSCs

Mauro Krampera • 31 May 2020
ISCT 2020
General Ifosfamide

Mauro Krampera, MD, PhD, of the University of Verona, Verona, Italy, discusses the pathogenesis of COVID-19 and the potential benefit of administrating mesenchymal stromal cells (MSCs) based on outcomes of patients with inflammatory disorders treated using this approach. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

More from Mauro Krampera

2:59
Functional dosing of MSC-derived extracellular vesicles for the prevention of GvHD
Mauro Krampera • 31 May 2020

Related Videos

0:55
Multivalent gamma-delta T-cells: promising agents for the treatment of cancers
Jürgen Kuball • 10 Feb 2023
1:26
Rapid CAR-T manufacturing and challenges in this space
Nina Worel • 9 Feb 2023
1:13
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells
Yasmin Nouri • 9 Feb 2023
2:08
Streamlining cell therapy manufacturing with CliniMACS Prodigy
Saskia Rösch • 6 Apr 2022
The content of VJRegenMed is intended for healthcare professionals